{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:03:46Z","timestamp":1773155026154,"version":"3.50.1"},"reference-count":54,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1517\/17425255.2011.557181","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T05:28:48Z","timestamp":1297142928000},"page":"371-380","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetic evaluation of ambrisentan"],"prefix":"10.1517","volume":"7","author":[{"given":"Mitchell S","family":"Buckley","sequence":"first","affiliation":[{"name":"Banner Good Samaritan Medical Center, Department of Pharmacy, 1111 E. McDowell Rd, Phoenix, AZ 85006, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M","family":"Wicks","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Department of Pharmacy, 1111 E. McDowell Rd, Phoenix, AZ 85006, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L","family":"Staib","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Department of Pharmacy, 1111 E. McDowell Rd, Phoenix, AZ 85006, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K","family":"Kirejczyk","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Department of Pharmacy, 1111 E. McDowell Rd, Phoenix, AZ 85006, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S","family":"Varker","sequence":"additional","affiliation":[{"name":"Banner Good Samaritan Medical Center, Department of Pharmacy, 1111 E. McDowell Rd, Phoenix, AZ 85006, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie J","family":"Gibson","sequence":"additional","affiliation":[{"name":"St. Joseph's Hospital & Medical Center, Department of Pharmacy, 350 W. Thomas Rd, Phoenix, AZ 85013, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy P","family":"Feldman","sequence":"additional","affiliation":[{"name":"Arizona Pulmonary Specialists, Ltd, 3330 N Second St. Suite 300, Phoenix, AZ 85012, USA ; ;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,2,8]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.01.024"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040291"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00075305"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.029"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.017"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00078207"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2006.11.002"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002727-200701000-00004"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707516"},{"key":"e_1_3_1_13_1","first-page":"1066","article-title":"Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis","volume":"11","author":"Raja SG","year":"2010","unstructured":"Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drug 2010;11:1066-73","journal-title":"Curr Opin Investig Drug"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s12187426"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2674"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.630715"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2006.11.009"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200307-957OC"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.01.057"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0767"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00054804"},{"key":"e_1_3_1_25_1","first-page":"CD004434","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension","volume":"3","author":"Liu C","year":"2009","unstructured":"Liu C, Chen J, Gao Y, Endothelin receptor antagonists in pulmonary arterial hypertension. Cochrane Database Syst Rev 2009;3:CD004434","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s3057"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.04.050"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.07.033"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2009.09.008"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1028"},{"key":"e_1_3_1_32_1","doi-asserted-by":"crossref","unstructured":"Cartin-ceba R Swanson K Iyer V Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension. Chest 2010. [Epub ahead of print]","DOI":"10.1378\/chest.10-0574"},{"key":"e_1_3_1_33_1","unstructured":"Letairis (ambrisentan) package insert. Gilead Sciences Inc. Foster City CA; 2009 Aug. Accessed October 2010"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/14796678.1.4.425"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200808030-00004"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03384.x"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008324180"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009335870"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/11534940-000000000-00000"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868150-00008"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565100-00003"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868030-00009"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"e_1_3_1_45_1","unstructured":"Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension (PAH) (Compass 2). Available from: www.clinicaltrials.gov\/ct2\/show\/NCT00303459?term=bosentan&rank=9 [Last accessed 15 October 2010]"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.012"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00113407"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.07.005"},{"key":"e_1_3_1_49_1","doi-asserted-by":"crossref","unstructured":"Ivy DD. Pharmacokinetics and safety of ambrisentan in pediatric patients with pulmonary arterial hypertension. Platform presentation at the American Thoracic Society International Conference San Diego CA; 2009","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A3330"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00028404"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-358OC"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00057906"},{"key":"e_1_3_1_53_1","unstructured":"Red Book 2010: Pharmacy's Fundamental Reference 2010 edition. Thomson Reuters Montvale (NJ); 2010"},{"key":"e_1_3_1_54_1","unstructured":"A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION). Available from: www.clinicaltrials.gov\/ct2\/show\/NCT01178073?term=ambition+study&rank=1 [Last accessed 15 October 2010]"},{"key":"e_1_3_1_55_1","unstructured":"Tracleer (bosentan) package insert. Actelion Pharmaceuticals US Inc. South San Francisco CA; 2009 Aug. Accessed October 2010"},{"key":"e_1_3_1_56_1","unstructured":"Thelin (sitaxsentan) package insert. Pfizer Canada Kirkland Quebec Canada; 2008 Nov. Accessed October 2010"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/17425255.2011.557181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:26:34Z","timestamp":1770917194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/17425255.2011.557181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,8]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1517\/17425255.2011.557181"],"URL":"https:\/\/doi.org\/10.1517\/17425255.2011.557181","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,8]]}}}